GLP-1 cost management

How to measure the long-term value of GLP-1s within employer healthcare costs

Employers are facing a difficult balancing act. GLP-1 medications offer significant opportunities to improve employee health, particularly for individuals living with obesity, diabetes and related chronic conditions. Yet their growing utilization is adding…

Medicare Plans Rarely Cover Anti-Obesity Drugs for Other FDA-Approved Purposes

Expanding uses for GLP-1s have not translated into broader coverage, new research shows.

Digital Health’s GLP-1 Strategy: “You Didn’t Come for the Drug. You Came for Health”

In a panel discussion, executives from Noom, Omada, Virta and Twin Health discussed how they are going beyond the pill in their GLP-1 strategy and responded to a question about whether they will exist two-to-three years from now.

#AHA26: Boehringer to seek approval of obesity shot, but gaining market share could be tricky

Boehringer Ingelheim will seek approval for its incretin shot survodutide for obesity next year, after a trial showed that the drug doesn’t increase patients’ risk of cardiovascular events like heart attacks and strokes. If the ...

EqualityGLP-1 Weight-Loss Drugs Will Be Covered for Fewer US EmployeesJust 53% of US employers now cover GLP-1s for weight loss, and nearly a third of those still offering the benefit are considering dropping it.Read more

From newsletter: Wall Street’s post-wave healthcare checkup Wall Street’s Healthcare Checkup After the Midterm Rout Physicians punched above their weight in the US midterms ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌…

Rising GLP-1 costs push employers to reconsider weight loss coverage

A WTW survey found weight loss drug coverage fell for the first time in three years. Here’s why employers are rethinking the benefit and what HR can do next.

The GLP-1 Wave Reaches Nursing Homes, Raising Questions About Cost and Care

What a Maturing GLP-1 Market Reveals About Modern Drug Markets and Their Future | Milbank Memorial Fund

The scale and ubiquity of GLP-1s give them a rare ability to illuminate the strengths and weaknesses of US drug markets and, increasingly, to reshape those markets.

The GLP-1 Dilemma: Medical Breakthrough Meets Financial Reality

A University of Pennsylvania panel of experts highlighted an unusual dilemma facing the American health care system: GLP-1 medications are highly effective treatments for obesity and several related chronic conditions, and their prices have fallen…

For Lilly, cash-pay is key in the US and, increasingly, abroad

Eli Lilly already knows Americans are willing to shell out hundreds of dollars a month for obesity drugs. Its bet on selling directly to patients helped it build a substantial

Employer GLP-1 coverage for weight loss dips for first time in 3 years: 6 notes